J. Anger, Principaux effets psychiques des stup??fiants : risques en milieu professionnel, Annales de Toxicologie Analytique, vol.14, issue.1, pp.68-73, 2002.
DOI : 10.1051/ata/2002042

A. Brisacier and A. Cadet-taïrou, Drogues, chiffres clés.6° édition. OFDT, 2015.

L. Karila, B. Megarbane, L. Chevillard, N. Benturquia, J. Laplanche et al., Nouveaux produits de synth??se??: revue des donn??es actuelles, La Presse M??dicale, vol.44, issue.4, pp.383-91, 2015.
DOI : 10.1016/j.lpm.2014.09.020

A. Cadet-taïrou, Profils et pratiques des usagers de nouveaux produits de synthèse, Tendances. ofdt. avril, 2016.

C. German, A. Fleckenstein, and G. Hanson, Bath salts and synthetic cathinones: An emerging designer drug phenomenon, Life Sciences, vol.97, issue.1, pp.2-8, 2014.
DOI : 10.1016/j.lfs.2013.07.023

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909723

E. Lahaie and M. Martinez, Agnès Cadet Tairou. Nouveaux produits de synthèse et internet, OFDT Tend. janv, vol.84, 2013.

M. Meyer, New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics, Archives of Toxicology, vol.17, issue.3, pp.2421-2465, 2016.
DOI : 10.2174/1389200217666151210142051

E. Tyrkkö, M. Andersson, and R. Kronstrand, The Toxicology of New Psychoactive Substances, Therapeutic Drug Monitoring, vol.38, issue.2, pp.190-216, 2016.
DOI : 10.1097/FTD.0000000000000263

F. Chavant, A. Boucher, L. Boisselier, R. Deheul, S. Debruyne et al., New Synthetic Drugs in Addictovigilance, Th??rapie, vol.70, issue.2, pp.179-89, 2015.
DOI : 10.2515/therapie/2015001

J. Zawilska and D. Andrzejczak, Next generation of novel psychoactive substances on the horizon ??? A complex problem to face, Drug and Alcohol Dependence, vol.157, pp.1-17, 2015.
DOI : 10.1016/j.drugalcdep.2015.09.030

C. Miliano, G. Serpelloni, C. Rimondo, M. Mereu, M. Marti et al., Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants, Disponible sur, 2016.
DOI : 10.3238/arztebl.2009.0464

E. Comission, Flash Eurobarometer 401 Young people and drugs: report

I. Medicaments-psychotropes, Consommations et pharmacodépendances In Paris; 2012. p. 321? 42. (Expertise collective) Disponible sur, p.32, 2072.

F. Beck, J. Richard, R. Guignard, O. L. Nézet, and S. Spilka, Les niveaux d'usage des drogues en France en 2014, Tendances. OFDT. mars, 2015.

H. Persson, G. Sjöberg, J. Haines, and J. Pronczuk-de-garbino, Poisoning Severity Score. Grading of Acute Poisoning, Journal of Toxicology: Clinical Toxicology, vol.106, issue.3, pp.205-218, 1998.
DOI : 10.1136/bmj.2.6028.153

O. Beck, L. Franzén, M. Bäckberg, P. Signell, and A. Helander, Toxicity evaluation of ??-pyrrolidinovalerophenone (??-PVP): results from intoxication cases within the STRIDA project, Clinical Toxicology, vol.35, issue.7, pp.568-75, 2016.
DOI : 10.3109/15563650.2014.981823

N. Sadones, S. Capiau, D. Kesel, P. Lambert, W. Stove et al., Spot them in the spot: analysis of abused substances using dried blood spots, Bioanalysis, vol.6, issue.17, pp.2211-2238, 2014.
DOI : 10.4155/bio.14.156

L. Ambach, H. Redondo, A. König, S. Weinmann, and W. , Rapid and simple LC-MS/MS screening of 64 novel psychoactive substances using dried blood spots, Drug Testing and Analysis, vol.397, issue.4, pp.367-75, 2014.
DOI : 10.1007/s00216-010-3571-5

M. Yegles, Un pi??ge dans l'analyse des cheveux : les traitements cosm??tiques, Annales de Toxicologie Analytique, vol.17, issue.4, pp.275-283, 2005.
DOI : 10.1051/ata:2005011

M. Liechti, Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling, Swiss Medical Weekly
DOI : 10.4414/smw.2015.14043

J. Nugteren-van-lonkhuyzen, A. Van-riel, T. Brunt, and L. Hondebrink, Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans, Drug and Alcohol Dependence, vol.157, pp.18-27, 2015.
DOI : 10.1016/j.drugalcdep.2015.10.011

J. «. Zawilska, ???Legal Highs??? ??? An Emerging Epidemic of Novel Psychoactive Substances, International Review of Neurobiology [Internet], vol.2015
DOI : 10.1016/bs.irn.2015.02.009

D. Wood, R. Sedefov, A. Cunningham, and P. Dargan, Prevalence of use and acute toxicity associated with the use of NBOMe drugs, Clinical Toxicology, vol.50, issue.2, pp.85-92, 2015.
DOI : 10.1097/PAF.0000000000000082

S. Botch-jones, J. Foss, D. Barajas, F. Kero, C. Young et al., The detection of NBOMe designer drugs on blotter paper by high resolution time-of-flight mass spectrometry (TOFMS) with and without chromatography, Forensic Science International, vol.267, pp.89-95, 2016.
DOI : 10.1016/j.forsciint.2016.08.008

P. Nikolaou, I. Papoutsis, M. Stefanidou, C. Spiliopoulou, and S. Athanaselis, 2C-I-NBOMe, an ???N-bomb??? that kills with ???Smiles???. Toxicological and legislative aspects, Drug and Chemical Toxicology, vol.78, issue.1, pp.113-122, 2015.
DOI : 10.1016/j.forsciint.2012.08.027

B. Dean, S. Stellpflug, A. Burnett, and K. Engebretsen, 2C or Not 2C: Phenethylamine Designer Drug Review, Journal of Medical Toxicology, vol.12, issue.2, pp.172-180, 2013.
DOI : 10.3109/10903127.2011.627108

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657019

M. Nelson, S. Bryant, and S. Aks, Emerging drugs of abuse, Disease-a-Month, vol.60, issue.3, pp.110-142, 2014.
DOI : 10.1016/j.disamonth.2014.01.001

M. Rech, E. Donahey, C. Dziedzic, J. Oh, L. Greenhalgh et al., New Drugs of Abuse, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol.31, issue.5, pp.189-97, 2015.
DOI : 10.1080/10550887.2012.735570

M. Castaneto, D. Gorelick, N. Desrosiers, R. Hartman, S. Pirard et al., Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications, Drug and Alcohol Dependence, vol.144, pp.12-41, 2014.
DOI : 10.1016/j.drugalcdep.2014.08.005

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253059

J. Tournebize, V. Gibaja, and J. Kahn, Acute effects of synthetic cannabinoids: Update 2015, Substance Abuse, vol.260, issue.1320, 2016.
DOI : 10.1155/2015/739149

R. Tittarelli, G. Mannocchi, F. Pantano, and F. Romolo, Recreational Use, Analysis and Toxicity of Tryptamines, Current Neuropharmacology, vol.13, issue.1, pp.26-46, 2015.
DOI : 10.2174/1570159X13666141210222409

A. Mcauley, G. Hecht, L. Barnsdale, C. Thomson, L. Graham et al., Mortality related to novel psychoactive substances in Scotland, 2012: An exploratory study, International Journal of Drug Policy, vol.26, issue.5, pp.461-468, 2015.
DOI : 10.1016/j.drugpo.2014.10.010

B. Kersten and M. Mclaughlin, Toxicology and Management of Novel Psychoactive Drugs, Journal of Pharmacy Practice, vol.12, issue.4, pp.50-65, 2015.
DOI : 10.1007/s00213-010-1911-y

L. Simmler, A. Rickli, Y. Schramm, M. Hoener, and M. Liechti, Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives, Biochemical Pharmacology, vol.88, issue.2, pp.237-281, 2014.
DOI : 10.1016/j.bcp.2014.01.024

P. Sainsbury, A. Kicman, R. Archer, L. King, and R. Braithwaite, Aminoindanes-the next wave of 'legal highs'? Drug Test Anal, juill, vol.3, issue.8, pp.479-82, 2011.

M. Coppola and R. Mondola, Research chemicals marketed as legal highs: The case of pipradrol derivatives, Toxicology Letters, vol.212, issue.1, pp.57-60, 2012.
DOI : 10.1016/j.toxlet.2012.04.019

U. Novel-psychoactive-treatment and . Network, Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances, 2015.

C. Davidson and F. Schifano, The potential utility of some legal highs in CNS disorders, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.64, pp.267-74, 2016.
DOI : 10.1016/j.pnpbp.2015.07.010

D. Baumeister, L. Tojo, and D. Tracy, Legal highs: staying on top of the flood of novel psychoactive substances, Therapeutic Advances in Psychopharmacology, vol.5, issue.2, pp.97-132, 2015.
DOI : 10.1177/2045125314559539

M. Zanda, P. Fadda, C. Chiamulera, W. Fratta, and L. Fattore, Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects, Behavioural Pharmacology, vol.27, issue.6, pp.489-96, 2016.
DOI : 10.1097/FBP.0000000000000241

H. Morris and J. Wallach, From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs, Drug Testing and Analysis, vol.81, issue.7-8, pp.614-646, 2014.
DOI : 10.1016/j.mehy.2013.03.030

F. Schifano, L. Orsolini, D. Papanti, G. Corkery, and J. , Novel psychoactive substances of interest for psychiatry, World Psychiatry, vol.12, issue.1, pp.15-26, 2015.
DOI : 10.1080/0968763042000275326

2. La, NBOMe provoque des hallucinations à des doses de 50 à 250 microgrammes. Il y a un grand risque d'overdose lié à des erreurs de dosage

E. Europe, les cathinones les plus utilisées sont la 4-méthylméthcathinone (méphédrone), la 4-méthyléthylcathinone (4-MEC), la méthylone, p.4

. Depuis, plus de 150 cannabinoïdes de synthèses ont été identifiés (30), appartenant à 14 familles chimiques différentes, ce qui fait d'eux le plus large groupe de NPS (16) source

. De-ce-fait, même si les tryptamines ont majoritairement des effets hallucinogènes, certaines présentent aussi des effets stimulants (40) Ainsi au cours d'intoxications ont peut observer un syndrome sérotoninergique et sympathomimétique

. Jusqu-'en and . Mai, 6-méthylènedioxy-2-aminoindane (MDAI), le 5-iodoaminoindane (5-IAI) et le 2-aminoindane (2-AI) sont les molécules les plus représentées de ce groupe. Récemment il y a eu une augmentation des rapports à l'Early Warning Advisory (EWA) concernant les dérivés N-alkyl, comme le N-méthyl-2-aminoindane (NM?2AI)(45) source, 2015.

L. Kétamine and . La-phéncyclidine, La kétamine est depuis longtemps détourné de son usage médical et est très populaire comme drogue dissociative. Il a été montré que la kétamine est à l'origine d'une urotoxicité, c'est ainsi qu'est apparue sur le marché en 2010 la méthoxétamine (2-(3-Méthoxyphényl)-2- (éthylamino) cyclohexan-1-one), 1950.

. La-méthoxétamine-a-une-structure-similaire-À-la-kétamine, Elle agit également comme antagoniste non compétitif des récepteurs glutamate N-méthyl D-aspartate (NMDA), et est un agoniste des récepteurs cholinergiques muscariniques et des récepteurs sérotoninergiques 5-HT-2